Answers are grounded in this paper and cite their sources.
We continue our series of editorials on the various subtypes of articles that are included in JU Open Plus. In this editorial, we will focus on opportunities for authors reporting on rare conditions including rare tumors, which are defined by the National Cancer Institute (NCI) as cancers that occur in fewer than 15/100,000 patients per year.1 Rare conditions are inherently challenging to study given the frequency with which they occur. JU Open Plus provides several formats to share data and elevate the care of patients with rare conditions. Case Report: The varied clinical presentations and management strategies for rare conditions lead to knowledge gaps. Case reports help fill this void by shedding light on how patients with rare conditions present, are evaluated, and treated. In the early issues of JU Open Plus, case reports highlighting a variety of benign, pediatric, and malignant conditions provide invaluable insight into novel diagnostics, treatments, and presentations for uncommon disease states.2-4 Case reports provide substantial latitude for authors to present rare conditions. Images of clinical examination findings and diagnostic testing (such as imaging studies and pathology slides) are useful tools for providers that may encounter such conditions in the future. Novel diagnostic approaches, including molecular sequencing, can also be shared. Intraoperative images enhance case reports by providing readers with techniques and maneuvers to manage rare conditions. Case reports also provide a forum for the author team to review the pertinent literature surrounding a rare condition, helping bridge knowledge gaps. Case reports are appealing to scholars across the spectrum—from trainees who are interested in sharing a unique case to seasoned practitioners who remain amazed to see conditions they have not encountered even after years of practice. Case Series: Case series are a natural extension of case reports for further investigation of rare conditions. Case series are often single or multi-institutional efforts reporting on a small cohort of patients. Case series provide the opportunity to enhance the literature for a rare condition by (1) publishing further information on presentation, evaluation, and management of a rare condition; (2) sharing novel treatment approaches for patients with rare conditions; and (3) disseminating experiences with new technologies and surgical approaches.5-7 Case series are an ideal format for sharing preliminary data, including when long-term follow-up is not available. This format provides authors with considerable freedom as unstructured manuscripts that allow the author to focus on data and discussion that is most relevant to the case series. Like case reports, case series are often imaging-heavy documents covering clinical presentation, diagnostics, novel techniques, and intraoperative photographs, as we have seen within our initial case series at JU Open Plus. Case series have the potential to be highly cited articles, particularly for novel diagnostic and therapeutic approaches. For rare conditions, case series are invaluable contributions to the literature that can help guide actual clinical management of conditions in the absence of level 1 data. Case series are ideal formats for the entire spectrum of our community, from aspiring urologists and scientists to senior academic and private practice urologists. MARCH 2024 ARTICLE REVIEWS Retrospective Study Merrill et al8 examined the important topic of cancer survivorship in terms of long-term follow-up needs. I recall being involved in committee meetings years ago designed to set up a survivorship clinic for our department that would be attended by advanced practice providers and to determine optimal follow-up protocols for them to follow. The challenge of the exercise was a relative paucity of data and guidance on follow-up after 5 years. In this study, the authors looked at the renal cell carcinoma model and used a multi-institutional database as its source. An interesting method of analysis was to emphasize looking at predictors of cancer versus non–cancer-specific survival and to determine the point in time at which the non-cancer events become the majority. The found that stage was the best predictor, and their Figure 2 shows the stratification of survival by cancer stage. They further refined the prediction by age categories which demonstrate significant differences in time when the non-cancer survival overtakes the cancer-specific survival. Given the costs and potential financial toxicity implications of “never-ending” cancer treatment follow-up, this article gives some rationale as to when follow-up can be discontinued. Rare Conditions Testicular carcinoma is a relatively rare entity, despite being one of the higher incident tumors in young men. Recurrences are generally detected with tumor markers and/or imaging. Faber et al9 report on a testicular cancer case with a recurrent cystic mass in the retroperitoneum shown on imaging at the stage where the primary tumor had been removed, but tumor markers remained elevated. The mass was unchanged after chemotherapy with normalized markers, and a retroperitoneal lymph node dissection identified the mass as associated with the duodenum. Histopathology showed a duodenal duplication cyst. The authors describe the literature on these cysts and suggest this may be the first report of one masquerading as metastatic testis cancer. The authors provide great images to review. Two other articles from Kaye et al10 and Qian et al11 are part of the March issue and were reviewed in the last month's editorial. People, Places, and Things This month's editorial features the 2024 European Association of Urology, which met in Paris, France, from April 5 to 8. This was a fabulous event packed into 3½ busy days of programing. I was pleased to see several of our editorial board members on the program and enjoyed catching up with BJUI team from my past editorial work. The city looked a bit different this year because there is construction all over town in preparation for the 2024 summer Olympics. I look forward to seeing more meeting highlights. From the prostate cancer sessions I attended, I can point to 3 significant presentations. Veeru Kasivisvanathan reported results from his trial comparing multiparametric with bimetric prostate MRI. The comparison showed no significant difference if image quality was high. This finding may simplify and speed up access to MRI. The EAU guidelines decided to change extended pelvic lymph node dissection to an option rather than a mandate, given the lack of curative effect and potential side effects. Several European groups are leading the charge toward improving prostate cancer screening to better use identification of higher risk groups, biomarkers, and imaging. Enjoy our monthly pictorial including Figures 1-3 showing people from the 2024 EAU and Figures 4-9 showing highlights from the venue of Paris.Figure 1.: People. Large association meetings are a natural opportunity for working groups to meet. At the 2024 European Association of Urology (EAU), our colleagues from the British Journal of Urology International had a group dinner—combining teams from both the flagship journal and our colleagues in open access publishing from BJUI Compass.Figure 2.: People. Adam Kibel (right) from Brigham and Woman’s Hospital in Boston delivered the Society of Urologic Oncology lecture at the 2024 EAU and received his certificate from program co-chair Peter Albers from Germany.Figure 3.: People. Many JUOP editors were featured speakers at the 2024 EAU including (a) Raphael Coelho, (b) Alicia Morgans, (c) Prokar Dasgupta who won the 2024 EAU Innovators award, and (d) Bernardo Rocco (middle—moderating at the European Robotic Urology Society).Figure 4.: Places. While in Paris, a great place to visit is the Sacré-Coeur Basilica, including the 222 step staircase leading to the top. If you are a fan of the John Wick movie series, you will be able to relive his epic night fight scene on the way to his dual at dawn.Figure 5.: Places. The Sacré-Coeur Basilica on top of Montmartre overlooking Paris.Figure 6.: Places. The Eiffel Tower looks a little different this year as this site and several others in the city prepare for the 2024 summer Olympic Games. I have stunning pictures of the tower lit up at night, but did you know that night shots of the tower are copyright protected?Figure 7.: Places. Paris mixes its history and monuments with everyday busy life—from the Arc de Triomphe and the Champs-Élysées.Figure 8.: Places. This picture of Notre Dame was shot during the 2018 World Endourology Society meeting in Paris—the famous cathedral suffered a devastating fire just a few months later, but is under restorations set to complete in 2024.Figure 9.: Things. Paris is often called the city of love. Many tourist areas are known for couples putting their names on padlocks and attaching them to various railings as symbols of love—to last forever, or until city politicians decide to cut them down. From Montmartre hill.
No takes yet. Share an insight, caveat, or question.
Bagrodia et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: